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Abstract
Introduction: Granulocytic sarcoma (GS) is an extramedullary disease which is composed of immature myeloid
cells or myeloblasts and usually occurs in association with acute myeloid leukemia (AML), as an initial presentation
or a relapse. GS has been associated with various cytogenetic abnormalities, particularly with the t(8;21)
translocation and less frequently the inv(16) type.
Case presentation: We present a rare case of GS of the small bowel, greater omentum and peritoneum, which
caused obstruction, in a patient with AML associated with a CBFb/MYH11 fusion gene and an inv(16) (p13q22). In
this patient there was only mild myeloid hyperplasia in bone marrow aspiration but molecular analysis identified a
CBFb-MYH11 fusion and inv(16) (p13;q22).
Conclusion: Because of its nonspecific clinical and radiologic findings, this entity can be misdiagnosed and can
mimic other solid neoplasms, making it a diagnostic challenge. In a GS with no or minimal morphological changes
in bone marrow aspiration it is very important to perform a cytogenetic analysis to benefit from the diagnosis and
therapeutic strategy.
Background
Myeloid sarcoma represents an extramedular tumour of
myeloblasts and/or immature myeloid cells [1]. Previous
terms used to describe this entity include chloroma,
extramedullary myeloid tumour, and granulocytic sar-
coma (GS). Chloroma was the initial term used to
describe these neoplasms, due to gross greenish appear-
ance identified in some lesions [2]. The World Health
Organization classification of haematopoietic tumours
divides myeloid sarcoma into two major categories [1].
The more common form is GS, composed mainly of
myeloblasts, neutrophils, and myeloid precursors. The
less common form is monoblastic sarcoma, which is
tipically composed of monoblasts and is associated with
acute monoblastic leukemia. GS can occur in virtually
any anatomic site, with a particular predilection for skin,
bone/spine, lymph nodes, soft tissue and genitourinary
tract [2,3]. Involvement of gastrointestinal tract is
uncommon (7%) and the most frequently involved
region in this system is the small bowel (10%) [2,4].
GS may present in association with acute myeloid leu-
kemia (AML), either as an initial presentation or as a
relapse. It may also signal impending blast crisis in the
setting of a myeloproliferative disorder or leukemic
transformation in myelodysplastic syndrome. Less com-
monly, it may also occur as an isolated mass in non-leu-
kemic patients (primary GS). In this later setting, the
majority of untreated patients progress to AML within
11 months [2,5]. GS in the setting of AML occurs most
frequently in acute myeloblastic leukemia with matura-
tion (French-American-British [FAB] M2) but has also
been described in the other subtypes including FAB M0,
M1, M3, M4, M5, and M7 [5].
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abnormalities, particularly with the t(8;21) translocation
[6] and less frequently the inv(16) type [7]. In cases pre-
viously reported to involve the small bowel or its
mesentery there has been an association with inv(16) or
the CBFb/MYH11 fusion gene or both [7,8].
We present a rare case of GS of the small bowel,
greater omentum and peritoneum, which caused
obstruction, in a patient with AML type FAB-M2 asso-
ciated with a CBFb/MYH11 fusion gene and an underly-
ing inversion of chromosome 16, inv(16) (p13q22).
Case report
A 41-year-old man was admitted with a 5-day history of
intermittent, crampy abdominal pain associated with
vomiting and fever. The patient also reported a 2-month
history of alternating diarrhea and constipation, abdom-
inal distension and weight loss.
On admission, the patient was normotensive, afebrile
and tachycardic. Generalized abdominal tenderness was
noted on palpation, with hyperactive bowel sounds and
no guarding or rigidity. The patients also presented
bilateral lower extremity edema. No petechia, lymphade-
nopathy, or hepatosplenomegaly were present. The
remainder physical examination was unremarkable.
Laboratory examination including a complete blood
count, erythrocyte sedimentation rate, liver and renal
profile were normal. Stool and blood cultures were
negative. Multiple air fluid levels were noted on an
upright abdominal radiograph. Enhanced computed
tomography (CT) of the abdomen (Figure 1, 2) showed
ascitis, dilated loops of small bowel with concentric
mural tickening, diffuse peritoneal tickening with multi-
ple peritoneal masses, and infiltration of the mesentery
and the greater omentum. No lymphadenopathy was
seen. Ultrasound-guided paracentesis was performed,
and cytologic evaluation of the ascitic fluid showed a
cell population with a blastic appearance presenting
multilobular nuclei, prominent nucleoli and cytoplasm
scant. Immunohistochemistry study revealed positivity
for myeloperoxidase (MPO) and CD68. The neoplastic
cells were negative for T-cell markers (CD3, CD5) and
for B-cell markers (CD20, CD79a). During hospital stay,
the patient’s condition steadily deteriorated, and he
developed increasing abdominal girth and ascitis and
experienced worsening diarrhea, continued weight loss,
abdominal pain, and lower extremity edema. With con-
cern for possible myeloid neoplasm and the presence of
subacute intestinal obstruction the patient was sched-
uled to undergo an exploratory laparotomy. On opera-
tion, multiple nodular masses in mesentery and small
bowel causing luminal narrowing were seen. Laparotomy
findings also included ascitis, and multiple masses on
the greater omentum and tickening of the peritoneum.
Resection of a clear and evident stenotic segment of
small bowel with primary anastomosis and biopsies of
the greater omentum and the peritoneum was per-
formed. Samples from ascitic fluid were also taken. The
jejunal segment that was resected was 14 cm long and
had one tumor that was 4 cm long. Histopathology
(Figure 3A) showed a transmural infiltrate, extending to
the adjoining mesentery, of poorly differentiated pleo-
morphic cells with numerous interspersed eosinophils.
At higher magnification, the cells had prominent mitotic
figures, large irregular nuclei, and scant cytoplasm.
Immunohistochemical staining (Figure 3B) was strongly
positive for MPO, lisozyme and Bc12, and negative for
CD10 and Cyclin D1. Similar findings were also found
in biopsies of the greater omentum and the peritoneum.
Since the final diagnosis was GS, the patient was investi-
gated for leukemia. Flow cytometric analysis performed
on the ascitic fluid sample showed the expression of
CD13, CD33, CD34, CD117 and HLA-DR. A bone
Figure 1 Abdominal CT scan showing: A) infiltration of the
mesentery and the peritoneum and B) ascitis and wall
tickening of small bowel.
Figure 2 Abdominal CT scan reveals multiple nodular masses
in mesentery and small bowel causing luminal narrowing
(sagittal section).
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served megakaryocytes, normoblastic erythroid cells,
mild myeloid hyperplasia, no increase in blasts and no
dysplasia. Molecular analysis of the bone marrow cells
using reverse transcriptase polymerase chain reaction
(RT-PCR) identified a CBFb-MYH11, “type A” fusion
transcript with an underlying inversion of chromosome
16, inv(16) (p13;q22). An insertion of FLT3 internal tan-
dem duplication (FLT3-ITD)i ne x o n1 4w a sf o u n di n
molecular study of ascitic fluid and intestinal biopsy.
According to these data, the diagnoses of acute myeloid
leukemia (AML) with inv(16) and FLT3-ITD-positive,
M2 in the FAB classification, and granulocytic sarcoma
in abdomen were made. Induction chemotherapy for
AML with idarubicin and cytosine arabinoside (3+7
regime) was started. The clinical course was complica-
ted by catheter-related sepsis. Abdominal symptoms
worsened dramatically in 1 week, so he received only
one cycle of treatment. After recovery from post-
chemotherapy, radiotherapy was administered. A total
dose of 22.4 Gy was administered in 14 fractions over
3 weeks (20 days). After radiotherapy, the patient
improved considerably, he gained weight and abdominal
pain and distension disappeared. CT scan showed
absence of ascitis and a clear decrease in the tickenning
of small bowel. Two months after diagnosis of GS, the
patient is about to restart chemotherapy.
Discussion
GS is a rare entity that represents a challenging diagno-
sis that can present clinically, radiologically, and histo-
pathologically similar to several other processes. This
disease has been reported to occur in just about every
anatomic location imaginable. GS may present as either
isolated or multiple lesions involving one or more organ
systems, and lesions may be synchronous or metachro-
nous. In a large series, Yamauchi and Yasuda [5] noted
that the majority of reported cases presented as isolated
masses. However, patients with multiple lesions, up to
four organs systems involved at one time, were also
described. In patients with GS involving the small
bowel, the age of presentation varies from 8 to 69 years,
with the majority occurring in male [4]. Ileum is the
most frequently involved region of the gastrointestinal
tract [4,9], while its presence in the jejunum is rare [10].
Even more rare is the synchronous involvement of the
jejunum and the greater omentum [11], or as in the
patient reported here, who had a concomitant involve-
ment of jejunum, greater omentum and peritoneum.
The majority of anatomical sites where GS develops
are associated with little to no clinical manifestations
and are discovered at autopsy [12]. In contrast, GS in
the gastrointestinal tract generally produces symptoms
that are often non-specific, as abdominal pain, vomiting,
fever, diarrhea, and weight loss [9]. The patients may
also present with intussusception [10], gastrointestinal
bleeding [13], perforation [9], anasarca and chronic ane-
mia [14], and obstruction [8,11]. Initially, our patient
presented with non-specific symptomatology until he
was adimitted for obstruction.
Most patients with GS tend to have leukemia at pre-
sentation, or they will eventually develop leukemia. The
patient reported here is one of the rare cases in which
abdominal GS coincided with the onset of AML type
FAB-M2 associated with a CBFb/MYH11 fusion and inv
(16) (p13;q22). In a recent review, Zhang et al [15]
describe that until 2010, only 20 cases of GS involved
with inv(16) have been reported. The chromosome kar-
yotypes of these patients were many and varied. How-
ever, all cases had the inv(16) karyotipic abnormality or
positive CBFb/MYH11 fusion gene. AML type FAB-M2
is usually associated with t(8;21) which is more prone to
Figure 3 Photomicrography of small bowel biopsy revealing: A)
a infiltrate of poorly differentiated pleomorphic cells with
prominent mitotic figures and scant cytoplasm (hematoxylin and
eosin stain × 400) and B) Immunohistochemical stain for MPO
showing staining of the tumour cells (myeloperoxidase × 400).
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two types of rearrangements involve the core binding
factor gene. The mechanism of the occurrence of GS
may be related to the deregulation of the core binding
factor transcription factors involved in cell recognition
and adhesion [16].
The wide variety of manifestations of GS often make
the diagnosis very difficult; gastrointestinal involvement
is very unusual and we must maintain a high index of
suspicion. The diagnosis of GS can be supported with
the use of multiple modalities including histochemical
and immunoperoxidase stains, conventional cytoge-
netics, fluorescent in situ hybridization cytogenetics, and
flow cytometry. These techniques are especially impor-
tant in primary GS, in which a previous diagnosis of leu-
kemia or myelodysplastic syndrome has not been made
[4,5]. The correct diagnosis can be derived with the aid
of histochemical and immunoperoxidase stains such as
naphtol-ASD-chloroacetate esterase, lysozime, CD34,
CD117, and MPO [2,17], as in our case. Flow cytometry
also is helpful in identifying blast populations expressing
stem cell (CD34), myeloid (CD13, CD33, CD117, MPO),
and/or monocytic (CD11c and CD14) antigens [4]. In
our patient, a flow cytometric analysis performed on the
ascitic fluid was helpful, as previously reported [14].
Conventional cytogenetics and fluorescent in situ hybri-
dization studies are probably most useful in identifying
specific characteristics present in previous lesions as a
sign of relapse or residual disease. Specific cytogenetic
abnormalities most frequently associated with GS
include t(8;21) and inv(16) (p13;q22) [4,15]. Most cases
of primary GS will develop AML. Although there are
reports of primary GS occurring prior the diagnosis of
AML [8,11], it is very important to perform bone mar-
row cytogenetic in a GS before it is coined as primary
GS [18]. This fact was demonstrated in the current case
report, where the patient showed only mild myeloid
hyperplasia in bone marrow aspiration but molecular
analysis identified a CBFb-MYH11 fusion and inv(16)
(p13;q22). Hence, it might not be appropriate to label a
GS as primary when bone marrow examination shows
no or minimal morphological changes but specific cyto-
genetic abnormalitiy to a particular disease such as
CBFb-MYH11.
GS can be difficult to diagnose, especially in cases that
are aleukemic, and it may be mistaken for diffuse large
cell lymphoma of the small bowel [7]. Therefore, the
diagnostician should maintain a high index of suspicion
when encountering an atypical presentation mimicking
lymphoma, lymphocytic infiltrate, or autoimmune disease
[19]. Timely accurate diagnosis and subclassification is
important as prompt treatment with appropriate therapy
may prevent the developmen to fal e u k e m i cp h a s ea n d
improve complete response rates and overall survival [7].
In the treatment of GS, systemic chemotherapy, surgical
resection, radiotherapy, peripheral stem cell/bone mar-
row transplantation, or a combination of these
approaches are used on a case-by-case basis. However, it
remains uncertain what constitutes the best treatment in
GS-associated AML patients. Surgery is not usually the
first option, and it is only indicated in the event of com-
plications like bleeding or obstruction [10], as in our
patient. Although only a few large series comparing treat-
ment modalities of GS are available in the literature
[2,20], systemic chemotherapy for AML seems to offer
the most benefit. In this regard, Lan et al [21] have
pointed out that early diagnosis with biopsy and early
chemotherapy seems to improve survival outcome but
local radiation or surgery seems to improve symptoms
but does not influence survival outcomes.
Leukemia with inv(16) (p13;q22) translocation or
CBFb-MYH11 fusion gene is a especial type which is
usually sensitive to chemotherapy and carries a better
prognosis than some other leukemia types. It has also
been reported that GS reduced the overall survival in t
(8;21) AML cases [20] but GS with inv(16) seems not to
affect clinical outcome [15]. Further investigation is still
necessary to identify the clinical significance of inv(16)
of GS and to choose appropriate therapeutic strategy.
Activating FLT3 mutations occur in approximately 40%
of cytogenetically normal AML patients and the most
frequent activating mutatio n si sF L T 3 - I T D ,w h o s ep r e -
sence is associated with resistence to chemotherapy and
inferior outcome [22]. This unfavorable prognostic fac-
tor was found in our patient.
Conclusion
W ed e s c r i b ear a r ec a s eo fa b d o m i n a lG Si nap a t i e n t
with AML associated with a CBFb/MYH11 fusion and
inv(16) (p13q22). Because of its nonspecific clinical and
radiologic findings, this entity can be misdiagnosed and
can mimic other solid neoplasms, making it a diagnostic
challenge. In a GS with no or minimal morphological
changes in bone marrow aspiration it is very important
to perform a cytogenetic analysis. Although all patients
should be treated with chemotherapy for AML, radio-
therapy and surgery are indicated in appropriate clinical
settings.
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